Nuvalent, Inc. Income Statement
NUVL / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| SG&A Expense | $107.3M | $62.6M | $36.2M | $22.4M | $10.3M | $1.5M |
| R&D Expense | $307.0M | $217.8M | $113.2M | $63.7M | $35.6M | $15.4M |
| Operating Income | -$414.3M | -$280.4M | -$149.5M | -$86.1M | -$45.8M | -$16.9M |
| Income Tax | $585.0K | $764.0K | $0 | $0 | - | - |
| Net Income | -$425.4M | -$260.8M | -$126.2M | -$81.9M | -$46.3M | -$14.6M |
| EPS (Basic) | -$5.85 | -$3.93 | -$2.17 | -$1.65 | -$2.13 | -$5.08 |
| EPS (Diluted) | -$5.85 | -$3.93 | -$2.17 | -$1.65 | -$2.13 | -$5.08 |
| Shares Outstanding | 72.7M | 66.4M | 58.2M | 49.7M | 21.8M | 2.9M |